Welcome to our dedicated page for DFP Holdings SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DFP Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DFP Holdings's regulatory disclosures and financial reporting.
Oncology Institute, Inc. director Brad Hively reported selling 13,333 shares of common stock on December 15, 2025. The shares were sold at a volume‑weighted average price of $3.771921 per share, with actual sale prices ranging from $3.770 to $3.785. He used the proceeds to pay tax liabilities that arose from the vesting of a restricted stock unit (RSU) award on November 20, 2025, indicating the transaction was primarily tax-related.
After this sale, Hively beneficially owns 683,721 shares of Oncology Institute common stock, held directly.
TOI has a shareholder planning to sell 13,333 shares of common stock under Rule 144.
The shares were acquired as restricted stock from the issuer on 11/21/2025 and are planned to be sold around 12/15/2025 through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $50,290.74. The issuer had 98,381,340 shares of common stock outstanding.
TOI has a shareholder planning to sell 13,333 shares of common stock under Rule 144.
The shares were acquired as restricted stock from the issuer on 11/21/2025 and are planned to be sold around 12/15/2025 through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $50,290.74. The issuer had 98,381,340 shares of common stock outstanding.
Oncology Institute, Inc. director Gabriel Ling filed a Form 4 as a single reporting person in connection with Oncology Institute, Inc. common stock. The filing lists Ling’s role as a director of the company and shows an earliest transaction date of 12/01/2025, but the transaction tables in the excerpt do not display any specific share amounts, prices, or derivative positions.
Oncology Institute, Inc. director Gabriel Ling filed a Form 4 as a single reporting person in connection with Oncology Institute, Inc. common stock. The filing lists Ling’s role as a director of the company and shows an earliest transaction date of 12/01/2025, but the transaction tables in the excerpt do not display any specific share amounts, prices, or derivative positions.
The Oncology Institute, Inc. reported that board member Gabriel Ling resigned from its Board of Directors on November 26, 2025, with the resignation effective December 1, 2025. The company stated that Mr. Ling’s decision was not the result of any disagreement regarding its operations, policies, or practices, indicating a non-controversial departure. On December 1, 2025, the company issued a press release announcing his resignation and furnished it as an exhibit to this report.
The Oncology Institute, Inc. reported that board member Gabriel Ling resigned from its Board of Directors on November 26, 2025, with the resignation effective December 1, 2025. The company stated that Mr. Ling’s decision was not the result of any disagreement regarding its operations, policies, or practices, indicating a non-controversial departure. On December 1, 2025, the company issued a press release announcing his resignation and furnished it as an exhibit to this report.
Oncology Institute, Inc. (TOI) reported equity awards to a director on a Form 4. Director Anne McGeorge acquired 67,901 shares of common stock in the form of restricted stock units that vest in full on the issuer’s 2026 annual stockholder meeting date, subject to continued service. She also received 40,123 restricted stock units that were fully vested upon grant, both at a stated price of $0 per share. Following these transactions, she beneficially owned 291,370 shares of common stock directly.
Oncology Institute, Inc. (TOI) director reports new stock awards. A board member filed a Form 4 disclosing two grants of common stock in the form of restricted stock units on 11/20/2025. One award covers 50,926 restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, assuming continued service. The second award covers 40,123 restricted stock units that were fully vested upon grant. Both awards are shown at a price of $0 per share, reflecting that they are equity compensation rather than open-market purchases. After these grants, the director beneficially owns 268,302 shares of common stock in direct ownership.
Oncology Institute, Inc. (TOI) director equity grant reported
A director of Oncology Institute, Inc. reported receiving new equity awards in the form of restricted stock units (RSUs). On 11/20/2025, the reporting person acquired 46,296 shares of common stock through RSUs that will vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service. On the same date, the director also acquired 37,037 fully vested RSUs, with no cash price per share reported for either grant. Following these transactions, the director beneficially owns 333,539 shares of TOI common stock directly.
Oncology Institute, Inc. (TOI) director equity grants reported
A reporting person who serves as a director of Oncology Institute, Inc. disclosed the receipt of two grants of common stock in the form of restricted stock units on 11/20/2025. One grant covers 47,840 restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service through that date. The second grant covers 37,037 restricted stock units that were fully vested upon grant. Both entries show a price of $0, reflecting that these are equity awards rather than open-market purchases. After these grants, the reporting person beneficially owns 288,286 shares of common stock in direct ownership.
Oncology Institute, Inc. (TOI) director Mark L. Pacala reported equity awards on a Form 4 for transactions dated 11/20/2025. He acquired 46,296 shares of common stock in the form of restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, subject to continued service. He also acquired 35,494 restricted stock units that were fully vested upon grant, both at a stated price of $0 per share. Following these transactions, he beneficially owned 256,761 shares of common stock directly.
Oncology Institute, Inc. (TOI) reported a Form 4 for director Brad Hively covering equity awards on 11/20/2025. The filing shows two grants of common stock in the form of restricted stock units at a price of $0 per share. One grant for 41,667 shares consists of restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service through that date. A second grant for 32,407 shares consists of restricted stock units that were fully vested upon grant. Following these transactions, Hively beneficially owns 697,054 shares of common stock directly.